Literature DB >> 30635820

LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/β-catenin pathway.

Feixia Wang1, Wu Zhu2, Ruili Yang1, Wanhua Xie2, Daojun Wang3.   

Abstract

Studies have shown that long noncoding RNA Zinc finger E-box-binding homeobox 2 antisense RNA 1 (ZEB2-AS1) is involved in the progression of lung cancer, bladder cancer, and hepatocellular carcinoma. However, its role in the pathogenesis of gastric cancer remains unknown. The Wnt/β-catenin pathway contributes to the development of gastric cancer. ZEB2-AS1 expression was firstly detected in the gastric carcinoma tissue samples as well as in gastric cancer cells. Knockdown of ZEB2-AS1 was performed by ZEB2-AS1-shRNA, and the viability, migration, invasion, and apoptosis of gastric cancer cells were determined by CCK-8, scratch assay, transwell, and flow cytometry, respectively. Furthermore, levels of Ki-67, PCNA, VEGF, MMP9, epithelial-mesenchymal transition (EMT) markers (E-cadherin, Vimentin and ZEB2), cleaved caspase 3/8/9 and PARP, active β-catenin, c-Myc, cyclinD1, and AXIN2 were assayed by Western blot or real-time PCR. Additionally, the role and mechanism of ZEB2-AS1 were confirmed in a xenograft nude mouse model. We found ZEB2-AS1 expression was increased in gastric carcinoma samples, and it was correlated with tumor progression. Also, its expression was elevated in gastric cancer cells. Knockdown of ZEB2-AS1 reduced the proliferation, migration, invasion, and EMT, but increased the apoptosis of gastric carcinoma cells. Furthermore, ZEB2-AS1 downregulation remarkably suppressed the expression of Ki-67, PCNA, VEGF and MMP9, and the activation of Wnt/β-catenin signaling, whereas elevated the levels of cleaved caspase 3/8/9 and PARP in gastric cancer cells. And ZEB2 overexpression reversed the effects of ZEB2-AS1 downregulation on the proliferation, EMT and inactivation of Wnt/β-catenin signaling. Additionally, ZEB2-AS1 knockdown inhibited tumor growth, Ki-67 staining, and the expression of VEGF, MMP9, active β-catenin, c-Myc, cyclinD1, and AXIN2 in mice. In conclusion, ZEB2-AS1 promotes the tumorigenesis of gastric carcinoma that is related to the upregulation of ZEB2 and the activation of the Wnt/β-catenin pathway.

Entities:  

Keywords:  Gastric cancer; Long noncoding RNAs; Wnt/β-catenin; ZEB2; ZEB2-AS1

Mesh:

Substances:

Year:  2019        PMID: 30635820     DOI: 10.1007/s11010-018-03491-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  36 in total

Review 1.  Present and future status of gastric cancer surgery.

Authors:  Makoto Saka; Shinji Morita; Takeo Fukagawa; Hitoshi Katai
Journal:  Jpn J Clin Oncol       Date:  2011-01-17       Impact factor: 3.019

2.  XIST promotes gastric cancer (GC) progression through TGF-β1 via targeting miR-185.

Authors:  Quan Zhang; Baiyu Chen; Ping Liu; Jing Yang
Journal:  J Cell Biochem       Date:  2017-12-04       Impact factor: 4.429

3.  Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma.

Authors:  Feng Yang; Xuchao Xue; Jianwei Bi; Luming Zheng; Kangkang Zhi; Yan Gu; Guoen Fang
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-11       Impact factor: 4.553

Review 4.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  William H Allum; Jane M Blazeby; S Michael Griffin; David Cunningham; Janusz A Jankowski; Rachel Wong
Journal:  Gut       Date:  2011-06-24       Impact factor: 23.059

5.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

Review 6.  Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer.

Authors:  Wanli Yang; Jiaojiao Ma; Wei Zhou; Bo Cao; Xin Zhou; Zhiping Yang; Hongwei Zhang; Qingchuan Zhao; Daiming Fan; Liu Hong
Journal:  Expert Opin Ther Targets       Date:  2017-10-19       Impact factor: 6.902

7.  Identification of key lncRNAs in colorectal cancer progression based on associated protein-protein interaction analysis.

Authors:  Haishan Zhu; Jiajing Yu; Haifeng Zhu; Yusheng Guo; Shengjie Feng
Journal:  World J Surg Oncol       Date:  2017-08-10       Impact factor: 2.754

8.  The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch pathways.

Authors:  Kun Zhang; Xiaohui Han; Zhen Zhang; Lina Zheng; Zhimei Hu; Qingbin Yao; Hongmei Cui; Guiming Shu; Maojie Si; Chan Li; Zhemin Shi; Ting Chen; Yawei Han; Yanan Chang; Zhi Yao; Tao Han; Wei Hong
Journal:  Nat Commun       Date:  2017-07-26       Impact factor: 14.919

Review 9.  LncRNAs: key players and novel insights into diabetes mellitus.

Authors:  Xiaoyun He; Chunlin Ou; Yanhua Xiao; Qing Han; Hao Li; Suxian Zhou
Journal:  Oncotarget       Date:  2017-08-04

Review 10.  An emerging function of circRNA-miRNAs-mRNA axis in human diseases.

Authors:  Dawei Rong; Handong Sun; Zhouxiao Li; Shuheng Liu; Chaoxi Dong; Kai Fu; Weiwei Tang; Hongyong Cao
Journal:  Oncotarget       Date:  2017-07-10
View more
  17 in total

1.  LINC00200 contributes to the chemoresistance to oxaliplatin of gastric cancer cells via regulating E2F1/RAD51 axis.

Authors:  Mengxin Lin; Meifang Xu; Zongbin Xu; Zongqi Weng; Bingqiang Lin; Yanqin Lan; Qing Liu; Xiaoyan Lin; Jie Pan
Journal:  Hum Cell       Date:  2021-04-06       Impact factor: 4.174

2.  Long non-coding RNA ZEB2-AS1 regulates osteosarcoma progression by acting as a molecular sponge of miR-107 to modulate SALL4 expression.

Authors:  Yu Wang; Ning Liu; Ming-Yue Li; Mao-Fang Du
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

3.  The lncRNA TERC promotes gastric cancer cell proliferation, migration, and invasion by sponging miR-423-5p to regulate SOX12 expression.

Authors:  Jianhua Wang; Min Wu; Le Chang; Zhankui Jin; Xiaoli Yang; Dongliang Li; Jiaojiao Wang; Jie Qu; Qiang Hou; Xiaoyan Huang; Cuixiang Xu
Journal:  Ann Transl Med       Date:  2022-09

Review 4.  The regulatory roles and potential prognosis implications of long non-coding RNAs in gastric cancer.

Authors:  Yue Wang; Fan Yang; Qing Yang
Journal:  Histol Histopathol       Date:  2019-12-03       Impact factor: 2.303

5.  The long non-coding RNA OLC8 enhances gastric cancer by interaction with IL-11.

Authors:  Rongjia Zhou; Zhanbin Wu; Xixiang Deng; Haojun Chen
Journal:  J Clin Lab Anal       Date:  2019-07-05       Impact factor: 2.352

6.  The long non-coding RNA SNHG12 promotes gastric cancer by activating the phosphatidylinositol 3-kinase/AKT pathway.

Authors:  Rui Zhang; Yuan Liu; Hui Liu; Wei Chen; Hui-Ning Fan; Jing Zhang; Jin-Shui Zhu
Journal:  Aging (Albany NY)       Date:  2019-12-05       Impact factor: 5.682

7.  Chinese Herbal Formulas Miao-Yi-Ai-Tang Inhibits the Proliferation and Migration of Lung Cancer Cells through Targeting β-Catenin/AXIN and Presents Synergistic Effect with Cisplatin Suppressing Lung Cancer.

Authors:  Bo Li; Wei Zhang; Tao Tan; Wei Liu; Xian Luo; Jun Zhang; Yi Yang; Ruogu Li; Zhengxing Ge
Journal:  Biomed Res Int       Date:  2020-01-16       Impact factor: 3.411

Review 8.  Long non-coding RNAs in gastric cancer: New emerging biological functions and therapeutic implications.

Authors:  Huidan Tan; Shouyue Zhang; Jin Zhang; Lingjuan Zhu; Yanmei Chen; Hongmei Yang; Yi Chen; Yang An; Bo Liu
Journal:  Theranostics       Date:  2020-07-11       Impact factor: 11.556

9.  Long noncoding RNA SNHG12 induces proliferation, migration, epithelial-mesenchymal transition, and stemness of esophageal squamous cell carcinoma cells via post-transcriptional regulation of BMI1 and CTNNB1.

Authors:  Duoguang Wu; Xiaotian He; Wenjian Wang; Xueting Hu; Kefeng Wang; Minghui Wang
Journal:  Mol Oncol       Date:  2020-06-18       Impact factor: 6.603

10.  Long non-coding RNA NCK1-AS1 promotes the tumorigenesis of glioma through sponging microRNA-138-2-3p and activating the TRIM24/Wnt/β-catenin axis.

Authors:  Lifa Huang; Xu Li; Hui Ye; Yajun Liu; Xiaolong Liang; Chao Yang; Lin Hua; Zhaoxian Yan; Xin Zhang
Journal:  J Exp Clin Cancer Res       Date:  2020-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.